Literature DB >> 8242626

Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.

S G Smith1, N L Lehman, R G Moran.   

Abstract

We have studied the cytotoxicity of 5,10-dideazatetrahydrofolate (DDATHF) and of D-1694 to human WiDr colonic carcinoma cells as a model system for the effects of pure inhibitors of either the de novo purine synthesis pathway or thymidylate synthesis. The growth of this cell line was inhibited by very low concentrations of either agent and the lethality of DDATHF and D-1694 was completely prevented by continuous exposure to either hypoxanthine or thymidine, respectively, indicating that these compounds were very potent metabolic inhibitors, each specific for one of these pathways. D-1694 was highly cytotoxic (> 3 logs of kill) after a 4-h exposure to 1 microM drug, or a 24-h exposure to very low concentrations (0.04 microM). On the other hand, the cytotoxicity of DDATHF was substantially lower, with 2 logs of cell kill requiring >> 100 microM with 4 h of exposure or approximately 40 microM for 72 h of exposure. Maximal cell kill induced by D-1694 was 5-6 logs, consistent with elimination of all viable cells except preexisting mutants. A maximum of 2-3 logs of cell kill was observed with DDATHF. Exposure of WiDr cells to either D-1694 or DDATHF caused striking cellular changes, but the morphologies of cells treated with the two drugs were remarkably different. D-1694-treated cells detached from the dish within 1-2 days after a megaloblastosis, whereas DDATHF-treated cells remained adherent to the dishes for at least 10 days after treatment. The addition of thymidine to D-1694-treated cultures or hypoxanthine to DDATHF-treated cells after up to 20 h of drug exposure completely prevented cytotoxicity of either drug. With longer exposures, cytotoxicity of both drugs progressively increased in spite of such rescue. Our results indicate that substantial (99-99.9%) tumor cell kill can be induced by a pure inhibitor of purine synthesis, but that the rate of commitment to cell death and the extent of cell kill is greater with a pure inhibitor of thymidylate synthesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8242626

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.

Authors:  Norman L Lehman; James P O'Donnell; Lisa J Whiteley; Robert T Stapp; Trang D Lehman; Kathleen M Roszka; Lonni R Schultz; Caitlin J Williams; Tom Mikkelsen; Stephen L Brown; Jeffrey A Ecsedy; Laila M Poisson
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

2.  Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.

Authors:  Yijun Deng; Xilin Zhou; Sita Kugel Desmoulin; Jianmei Wu; Christina Cherian; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

3.  Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter.

Authors:  Sita Kugel Desmoulin; Lei Wang; Eric Hales; Lisa Polin; Kathryn White; Juiwanna Kushner; Mark Stout; Zhanjun Hou; Christina Cherian; Aleem Gangjee; Larry H Matherly
Journal:  Mol Pharmacol       Date:  2011-09-22       Impact factor: 4.436

4.  Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.

Authors:  Sita Kugel Desmoulin; Yiqiang Wang; Jianmei Wu; Mark Stout; Zhanjun Hou; Andreas Fulterer; Min-Hwang Chang; Michael F Romero; Christina Cherian; Aleem Gangjee; Larry H Matherly
Journal:  Mol Pharmacol       Date:  2010-07-02       Impact factor: 4.436

5.  AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase.

Authors:  T J Boritzki; C A Barlett; C Zhang; E F Howland
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 6.  Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.

Authors:  A L Jackman; F T Boyle; K R Harrap
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

7.  Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.

Authors:  Yijun Deng; Yiqiang Wang; Christina Cherian; Zhanjun Hou; Steven A Buck; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2008-08-05       Impact factor: 7.446

8.  Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitors.

Authors:  John C Schmitz; Edward Chu
Journal:  Silence       Date:  2011-01-19

9.  Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity.

Authors:  Shao-yu Wu; Tian-min Chen; William H Gmeiner; Edward Chu; John C Schmitz
Journal:  Nucleic Acids Res       Date:  2013-02-28       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.